ClinicalTrials.gg
RecruitingNCT05968898ARCADESUpdated Jun 2, 2026

Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES

An interventional study of Optellum Virtual Nodule Clinic in Lung Cancer and Pulmonary Nodule, Solitary, sponsored by Abramson Cancer Center at Penn Medicine. Recruiting at 3 sites in United States. Open to participants aged 35 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
35 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine — 2 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Abramson Cancer Center at Penn Medicine.

Planned enrollment
4th of 20
300 · median 55
Started
2024
with 1 other
No phase
12 of 26
2 open now
Registered
20th of 26
by date

Among the 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine, this one is the 4th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 12 with no phase, and was the 20th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

2 of the 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 35 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine, or all of them as a file.
02

Study summary

This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.

Read the detailed description

Accurate malignancy risk stratification of pulmonary nodules (PNs) is critical to ensuring that cancer is diagnosed in a timely manner and patients do not undergo unnecessary diagnostic procedures. Preliminary data suggests that a radiomics-based lung cancer prediction (LCP) computer-aided diagnosis (CAD) tool is effective in risk stratifying PNs and may improve clinicians' PN management decisions. This is a pragmatic clinical trial evaluating the effect of this CAD tool on clinicians' management of PNs compared to usual care. Individuals eligible for this study will include adults aged 35-89 years who are scheduled to be evaluated at a Penn Medicine PN clinic for a newly discovered PN 8-30mm in maximal diameter on CT imaging. Exclusion criteria include lack of CT imaging data at the time of index clinic visit, thoracic lymphadenopathy by CT size criteria, presence of pulmonary masses (>3cm in maximal diameter), PNs with popcorn calcification (consistent with benign etiology), pure ground-glass subsolid PNs, a history of lung cancer, and history of any active cancer within 5 years. Enrolled participants will undergo 1:1 stratified randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care (clinician assessment) or 2) clinician assessment + CAD-based risk stratification using the LCP-CAD tool. The control arm will be usual care, defined as routine clinician assessment of PN malignancy risk. In the experimental arm, clinicians will be provided a report with the CAD tool estimate of malignancy risk for the PN being evaluated.

03

Conditions studied

  • Lung Cancer
  • Pulmonary Nodule, Solitary

Keywords

  • clinical effectiveness
  • clinical utility
  • artificial intelligence
  • medical decision-making
  • risk stratification
04

Who can participate

Ages eligible
35 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 35-89 years
  2. Scheduled to be evaluated at a UPHS PN clinic
  3. Newly discovered solid or part-solid indeterminate PN 8-30mm in maximal diameter on CT imaging within 60 days of index clinic visit
  4. Chest CT imaging meeting the technical requirements for compatibility with Optellum Virtual Nodule Clinic software

Exclusion criteria

Exclusion Criteria:

  1. Chest CT imaging with discrete mediastinal or hilar lymphadenopathy by CT size criteria (>10mm in maximal short-axis diameter on axial CT images)
  2. PNs with popcorn calcification (consistent with benign etiology)
  3. Pure ground-glass subsolid PNs (may be associated with lower risk of )
  4. PN previously seen on CT imaging >60 days prior to most recent CT
  5. More than one indeterminate PN 8-30mm in maximal diameter
  6. History of lung cancer
  7. History of active cancer within the previous 5 years
  8. Presence of a thoracic implant that impedes PN visualization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    Usual care (clinician assessment)

    In the usual care arm, clinicians will evaluate individuals with indeterminate pulmonary nodules as part of routine clinical care. No specific guidance regarding pulmonary nodule risk stratification will provided to evaluating clinicians.

  • Experimental
    Clinician assessment + CAD-based risk stratification

    In the experimental arm, evaluating clinicians will receive a Lung Cancer Prediction report from an artificial intelligence radiomics-based computer-aided diagnosis tool for risk stratification of pulmonary nodules.

    Device: Optellum Virtual Nodule Clinic

Interventions

  • DeviceOptellum Virtual Nodule Clinic

    The Optellum Virtual Nodule Clinic is an FDA-approved (Class II) device for risk stratification of pulmonary nodules. It uses a convolutional neural network to evaluate CT imaging data to provide an estimate of malignancy risk for indeterminate pulmonary nodules.

06

What researchers measure

Primary outcomes

  1. Appropriate management of pulmonary nodule

    The composite proportion of benign pulmonary nodules managed with imaging surveillance and malignant pulmonary nodules managed with biopsy or empiric treatment. Final pulmonary nodule diagnosis will be categorized as malignant or benign based on pathologic evaluation. If pathology is unavailable or inconclusive (i.e., the biopsy was non-diagnostic), pulmonary nodule resolution, shrinkage, or diameter stability at 12 months will be defined as a benign diagnosis.

    Time frame: 12 months

Secondary outcomes

  1. Timeliness of care

    For patients with malignant pulmonary nodules, defined as the number of days between the index clinic visit and diagnosis of malignancy and receipt of treatment for malignancy (i.e., surgical resection, radiation therapy).

    Time frame: 12 months

  2. Adverse events

    For patients undergoing biopsy, defined as procedural complications related to pulmonary nodule biopsy.

    Time frame: 12 months

  3. Diagnostic yield

    Using information found in pathology reports, defined as the proportion of biopsies with a definitive histopathologic diagnosis, for each type of diagnostic biopsy procedure.

    Time frame: 12 months

  4. Healthcare costs

    The costs of all imaging studies and diagnostic testing associated with the pulmonary nodule diagnostic process, based on Medicare allowed amounts (amount paid by Medicare and the amount paid by the beneficiary and/or third parties).

    Time frame: 12 months

07

Study locations

3 of 3 sites recruiting
  • Penn Medicine University City
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Roger Kim, MD, MSCE · Contact
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Roger Kim, MD, MSCE · Contact
  • Penn Medicine Washington Square
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
    • Roger Kim, MD, MSCE · Contact
08

References and documents

Publications

  • Kim RY, Oke JL, Pickup LC, Munden RF, Dotson TL, Bellinger CR, Cohen A, Simoff MJ, Massion PP, Filippini C, Gleeson FV, Vachani A. Artificial Intelligence Tool for Assessment of Indeterminate Pulmonary Nodules Detected with CT. Radiology. 2022 Sep;304(3):683-691. doi: 10.1148/radiol.212182. Epub 2022 May 24. PubMed 35608444 ↗
  • Kim RY, Oke JL, Dotson TL, Bellinger CR, Vachani A. Effect of an artificial intelligence tool on management decisions for indeterminate pulmonary nodules. Respirology. 2023 Jun;28(6):582-584. doi: 10.1111/resp.14502. Epub 2023 Apr 5. No abstract available. PubMed 37017091 ↗
  • Massion PP, Antic S, Ather S, Arteta C, Brabec J, Chen H, Declerck J, Dufek D, Hickes W, Kadir T, Kunst J, Landman BA, Munden RF, Novotny P, Peschl H, Pickup LC, Santos C, Smith GT, Talwar A, Gleeson F. Assessing the Accuracy of a Deep Learning Method to Risk Stratify Indeterminate Pulmonary Nodules. Am J Respir Crit Care Med. 2020 Jul 15;202(2):241-249. doi: 10.1164/rccm.201903-0505OC. PubMed 32326730 ↗
  • Baldwin DR, Gustafson J, Pickup L, Arteta C, Novotny P, Declerck J, Kadir T, Figueiras C, Sterba A, Exell A, Potesil V, Holland P, Spence H, Clubley A, O'Dowd E, Clark M, Ashford-Turner V, Callister ME, Gleeson FV. External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules. Thorax. 2020 Apr;75(4):306-312. doi: 10.1136/thoraxjnl-2019-214104. Epub 2020 Mar 5. PubMed 32139611 ↗
  • Paez R, Kammer MN, Balar A, Lakhani DA, Knight M, Rowe D, Xiao D, Heideman BE, Antic SL, Chen H, Chen SC, Peikert T, Sandler KL, Landman BA, Deppen SA, Grogan EL, Maldonado F. Longitudinal lung cancer prediction convolutional neural network model improves the classification of indeterminate pulmonary nodules. Sci Rep. 2023 Apr 15;13(1):6157. doi: 10.1038/s41598-023-33098-y. PubMed 37061539 ↗
  • Paez R, Kammer MN, Tanner NT, Shojaee S, Heideman BE, Peikert T, Balbach ML, Iams WT, Ning B, Lenburg ME, Mallow C, Yarmus L, Fong KM, Deppen S, Grogan EL, Maldonado F. Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules. Chest. 2023 Oct;164(4):1028-1041. doi: 10.1016/j.chest.2023.05.025. Epub 2023 May 25. PubMed 37244587 ↗
  • Kim RY. Radiomics and artificial intelligence for risk stratification of pulmonary nodules: Ready for primetime? Cancer Biomark. 2025 Jan;42(1):CBM230360. doi: 10.3233/CBM-230360. Epub 2024 Feb 6. PubMed 38427470 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jul 2029, 66 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 66 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartActual
Jan 9, 2024
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2030
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05968898
Responsible party
Roger Y. Kim (Assistant Professor of Medicine, Abramson Cancer Center at Penn Medicine) — Principal investigator
First posted
Aug 1, 2023
Start date
Jan 9, 2024
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Jun 2, 2026

Study contacts

Roger Y. Kim, MD, MSCE
Contact
roger.kim@pennmedicine.upenn.edu
215-662-3677
Anil Vachani, MD, MSCE
Contact
avachani@pennmedicine.upenn.edu
215-573-7931
Roger Y. Kim, MD, MSCE
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion